Multiple Sclerosis Journal - Experimental, Translational and Clinical最新文献_第9页

Identifying the white matter pathways involved in multiple sclerosis-related tremor using diffusion tensor imaging 利用扩散张量成像识别多发性硬化症相关震颤中涉及的白质通路

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2023-10-01 DOI: 10.1177/20552173231208271

Ahmed Bayoumi, Khader M. Hasan, Jorge Patino, Zafer Keser, Joseph A. Thomas, Refaat E. Gabr, Claudia Pedroza, Arash Kamali, Mya C. Schiess, Jerry S. Wolinsky, John A. Lincoln

{"title":"Identifying the white matter pathways involved in multiple sclerosis-related tremor using diffusion tensor imaging","authors":"Ahmed Bayoumi, Khader M. Hasan, Jorge Patino, Zafer Keser, Joseph A. Thomas, Refaat E. Gabr, Claudia Pedroza, Arash Kamali, Mya C. Schiess, Jerry S. Wolinsky, John A. Lincoln","doi":"10.1177/20552173231208271","DOIUrl":"https://doi.org/10.1177/20552173231208271","url":null,"abstract":"Background Tremor affects up to 45% of patients with Multiple Sclerosis (PwMS). Current understanding is based on insights from other neurological disorders, thus, not fully addressing the distinctive aspects of MS pathology. Objective To characterize the brain white matter (WM) correlates of MS-related tremor using diffusion tensor imaging (DTI). Methods In a prospective case-control study, PwMS with tremor were assessed for tremor severity and underwent MRI scans including DTI. PwMS without tremor served as matched controls. After tract selection and segmentation, the resulting diffusivity measures were used to calculate group differences and correlations with tremor severity. Results This study included 72 PwMS. The tremor group (n = 36) exhibited significant changes in several pathways, notably in the right inferior longitudinal fasciculus (Cohen's d = 1.53, q < 0.001) and left corticospinal tract ( d = 1.32, q < 0.001), compared to controls (n = 36). Furthermore, specific tracts showed a significant correlation with tremor severity, notably in the left medial lemniscus (Spearman's coefficient [ r s p] = −0.56, p < 0.001), and forceps minor of corpus callosum ( r s p = -0.45, p < 0.01). Conclusion MS-related tremor is associated with widespread diffusivity changes in WM pathways and its severity correlates with commissural and sensory projection pathways, which suggests a role for proprioception or involvement of the dentato-rubro-olivary circuit.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"136 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136198695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Detecting macromolecular differences of the CSF in low disability multiple sclerosis using quantitative MT MRI at 3T 使用定量MT MRI检测低残疾多发性硬化患者脑脊液的大分子差异

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2023-10-01 DOI: 10.1177/20552173231211396

Richard D Lawless, Colin D McKnight, Kristin P O’Grady, Anna JE Combes, Baxter P Rogers, Atlee A Witt, Mereze Visagie, Delaney C Houston, Logan E Prock, Francesca R Bagnato, Seth A Smith

{"title":"Detecting macromolecular differences of the CSF in low disability multiple sclerosis using quantitative MT MRI at 3T","authors":"Richard D Lawless, Colin D McKnight, Kristin P O’Grady, Anna JE Combes, Baxter P Rogers, Atlee A Witt, Mereze Visagie, Delaney C Houston, Logan E Prock, Francesca R Bagnato, Seth A Smith","doi":"10.1177/20552173231211396","DOIUrl":"https://doi.org/10.1177/20552173231211396","url":null,"abstract":"Background Imaging investigation of cerebrospinal fluid (CSF) in multiple sclerosis (MS) is understudied. Development of noninvasive methods to detect pathological CSF changes would have a profound effect on MS diagnosis and would offer insight into MS pathophysiology and mechanisms of neurological impairment. Objective We propose magnetization transfer (MT) MRI as a tool to detect macromolecular changes in spinal CSF. Methods MT and quantitative MT (qMT) data were acquired in the cervical region in 27 people with relapsing-remitting multiple sclerosis (pwRRMS) and 38 age and sex-matched healthy controls (HCs). MT ratio (MTR), the B 1 , B 0 , and R 1 corrected qMT-derived pool size ratio (PSR) were quantified in the spinal cord and CSF of each group. Results Both CSF MTR and CSF qMT-derived PSR were significantly increased in pwRRMS compared to HC ( p = 0.027 and p = 0.020, respectively). CSF PSR of pwRRMS was correlated to Expanded Disability Status Scale Scores ( p = 0.045, R = 0.352). Conclusion Our findings demonstrate increased CSF macromolecular content in pwRRMS and link CSF macromolecular content with clinical impairment. This highlights the potential role of CSF in processing products of demyelination.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"60 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136247615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Does the Multiple Sclerosis Impact Scale-29 (MSIS-29) have the range to capture the experience of fully ambulatory multiple sclerosis patients? Learnings from the ASCLEPIOS studies. 多发性硬化症影响量表-29（MSIS-29）是否有足够的范围来捕捉完全卧床的多发性痴呆症患者的经验？ASCLEPIOS研究的经验教训。

IF 2.8

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2023-09-28 eCollection Date: 2023-07-01 DOI: 10.1177/20552173231201422

Antoine Regnault, Angely Loubert, Róisín Brennan, Juliette Meunier, Christel Naujoks, Stefan Cano, Nicholas Adlard

{"title":"Does the Multiple Sclerosis Impact Scale-29 (MSIS-29) have the range to capture the experience of fully ambulatory multiple sclerosis patients? Learnings from the ASCLEPIOS studies.","authors":"Antoine Regnault, Angely Loubert, Róisín Brennan, Juliette Meunier, Christel Naujoks, Stefan Cano, Nicholas Adlard","doi":"10.1177/20552173231201422","DOIUrl":"https://doi.org/10.1177/20552173231201422","url":null,"abstract":"Background: Trials of disease-modifying therapies (DMTs) for multiple sclerosis (MS) often include patients with minimal disability. Patient-reported outcome instruments used in these trials have often not captured physical and psychological treatment effects concomitant with observed clinical benefits.Objective: To examine whether the Multiple Sclerosis Impact Scale-29 (MSIS-29) captures changes in the impact of MS in a sample of patients enrolled in the Phase 3 ASCLEPIOS studies (ofatumumab vs. teriflunomide).Methods: Measurement properties (i.e. item fit, reliability, and targeting) of the MSIS-29 were analyzed using Rasch measurement theory (RMT) in data from two phase 3 ofatumumab clinical trials including patients with relapsing-remitting or secondary progressive MS (N = 1882). Targeting of the MSIS-29 items to the patient population was explored within groups categorized by Expanded Disability Status Scale (EDSS) scores.Results: Under RMT analyses, both the Physical and Psychological Impact scales of the MSIS-29 were not appropriately targeted to the overall sample of patients. In particular, 49% and 30% of patients with an EDSS score ≤ 2.5 had fewer physical and psychological impacts, respectively, than would typically be captured by these MSIS-29 items compared to patients with EDSS scores of ≥ 3.Conclusion: The MSIS-29 is commonly used to evaluate the patient-reported physical and psychological impact of MS. However, it may be limited in evaluating changes associated with DMTs in patients with minimal disability.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231201422"},"PeriodicalIF":2.8,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0f/96/10.1177_20552173231201422.PMC10540592.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41166970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The association of upper respiratory infections with neuro-radiological course and attack rate of multiple sclerosis: Results from a large prospective cohort. 上呼吸道感染与多发性硬化症的神经放射学病程和发病率的关系：来自一个大型前瞻性队列的结果。

IF 2.5

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2023-09-25 eCollection Date: 2023-07-01 DOI: 10.1177/20552173231196992

Moein Ghasemi, Dorreh Farazandeh, Behnam Amini, Mona Sedaghat, Anahita Najafi, Simin Khayatzadeh Kakhki, Pouya Torabi, Niloofar Jafarimehrabady, Ali Bitaraf, Houria Shariati, Golsa Gholampour, Saminnaz Kazemi, Abdorreza Naser Moghadasi, Maryam Vajihinejad

{"title":"The association of upper respiratory infections with neuro-radiological course and attack rate of multiple sclerosis: Results from a large prospective cohort.","authors":"Moein Ghasemi, Dorreh Farazandeh, Behnam Amini, Mona Sedaghat, Anahita Najafi, Simin Khayatzadeh Kakhki, Pouya Torabi, Niloofar Jafarimehrabady, Ali Bitaraf, Houria Shariati, Golsa Gholampour, Saminnaz Kazemi, Abdorreza Naser Moghadasi, Maryam Vajihinejad","doi":"10.1177/20552173231196992","DOIUrl":"10.1177/20552173231196992","url":null,"abstract":"Background: Although upper respiratory infections (URIs) are linked to multiple sclerosis (MS) attacks, SARS-COV2 has not been compared to URIs for attack rates.Objectives: This study aimed to evaluate the attack rate and the results of neuroimaging in MS patients with URIs caused by COVID-19 and non-COVID-19 infections (NC-URI).Methods: From May 2020 to April 2021, we followed 362 patients with relapsing-remitting MS in a prospective cohort design. Patients were monitored regularly every 12 weeks; an magnetic resonance imaging (MRI) scan was performed at enrollment and every time a relapse occurred. Poisson analysis was used to determine exacerbation rate ratios (RR) and the MRI parameters were tested using chi-square analysis.Results: 347 patients with an average age of 38 and a female ratio of 86% were included. A RR of 2.24 (p < 0.001) was observed for exacerbations during the at-risk period (ARP). Attacks related to COVID-19 (RR = 2.13, p = 0.001) and NC-URIs (RR = 2.39, p < 0.001) were comparable regarding the increased risk of exacerbation (p = 0.62). Exacerbations within or outside the ARP did not significantly alter the number of baseline GAD-enhancing lesions (p > 0.05 for both).Conclusion: COVID-19 has been shown to increase the risk of MS exacerbations, like other viral URIs.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231196992"},"PeriodicalIF":2.5,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7d/37/10.1177_20552173231196992.PMC10521289.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41101046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Google Maps Timeline: An open-access digital tool to monitor walking abilities in people with multiple sclerosis. 谷歌地图时间线：一个开放获取的数字工具，用于监测多发性硬化症患者的行走能力。

IF 2.8

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2023-09-16 eCollection Date: 2023-07-01 DOI: 10.1177/20552173231202123

Daniele Caliendo, Anna Puca, Luigi Lavorgna, Antonio Carotenuto, Maria Petracca, Roberta Lanzillo, Vincenzo Brescia Morra, Marcello Moccia

{"title":"Google Maps Timeline: An open-access digital tool to monitor walking abilities in people with multiple sclerosis.","authors":"Daniele Caliendo, Anna Puca, Luigi Lavorgna, Antonio Carotenuto, Maria Petracca, Roberta Lanzillo, Vincenzo Brescia Morra, Marcello Moccia","doi":"10.1177/20552173231202123","DOIUrl":"10.1177/20552173231202123","url":null,"abstract":"Introduction: Gait impairment is common in multiple sclerosis (MS), but difficult to evaluate in clinical practice. In this proof-of-concept observational study, we compared walking ability recorded by Google Maps Timeline to conventional clinical measures in people with MS.Methods: We used open-access Google Maps Timeline to record the total number of days with walking activity, walking distance, walking time, and walking speed. Each Google Maps Timeline variable was included in a different stepwise linear regression model including all conventional clinical variables.Results: We included nine people with MS (age 43.1 ± 6.6 years; females 55.6%; disease duration 12.7 ± 3.1 years; median Expanded Disability Status Scale 3.0 (range 1.0-5.5)). Higher percentage of days with recorded walking was associated with lower Fatigue Severity Scale (p = 0.01), and higher MS Walking Scale (p = 0.04). Longer average daily walking distance was associated with shorter Timed-25 Foot Walking Test (p = 0.02), lower Expanded Disability Status Scale (p = 0.01), and higher Euro-Quality of Life (p = 0.04). Longer average daily walking time was associated with shorter Timed-25 Foot Walking Test (p = 0.03). Higher walking speed was associated with lower Fatigue Severity Scale (p = 0.04).Conclusion: Google Maps Timeline parameters provide actual estimates of daily walking activities in MS.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231202123"},"PeriodicalIF":2.8,"publicationDate":"2023-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/29/10.1177_20552173231202123.PMC10505345.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10309473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Overall and patient-specific comparative effectiveness of dimethyl fumarate versus teriflunomide: A novel approach to precision medicine applied to the German NeuroTrans Data Multiple Sclerosis Registry. 富马酸二甲酯与特立氟米特的总体和患者特异性比较有效性:一种应用于德国NeuroTrans数据多发性硬化症登记处的精准医学新方法。

IF 2.8

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2023-08-25 eCollection Date: 2023-07-01 DOI: 10.1177/20552173231194353

Xiaotong Jiang, Gabrielle Simoneau, Mel Zuercher, Yanic Heer, Philip van Hoevell, Adrian Harrington, Wanda Castro-Borrero, Carl de Moor, Fabio Pellegrini, Lu Tian, Arnfin Bergmann, Stefan Braune

{"title":"Overall and patient-specific comparative effectiveness of dimethyl fumarate versus teriflunomide: A novel approach to precision medicine applied to the German NeuroTrans Data Multiple Sclerosis Registry.","authors":"Xiaotong Jiang, Gabrielle Simoneau, Mel Zuercher, Yanic Heer, Philip van Hoevell, Adrian Harrington, Wanda Castro-Borrero, Carl de Moor, Fabio Pellegrini, Lu Tian, Arnfin Bergmann, Stefan Braune","doi":"10.1177/20552173231194353","DOIUrl":"10.1177/20552173231194353","url":null,"abstract":"Background: Multiple sclerosis (MS) comparative effectiveness research needs to go beyond average treatment effects (ATEs) and post-host subgroup analyses.Objective: This retrospective study assessed overall and patient-specific effects of dimethyl fumarate (DMF) versus teriflunomide (TERI) in patients with relapsing-remitting MS.Methods: A novel precision medicine (PM) scoring approach leverages advanced machine learning methods and adjusts for imbalances in baseline characteristics between patients receiving different treatments. Using the German NeuroTransData registry, we implemented and internally validated different scoring systems to distinguish patient-specific effects of DMF relative to TERI based on annualized relapse rates, time to first relapse, and time to confirmed disease progression.Results: Among 2791 patients, there was superior ATE of DMF versus TERI for the two relapse-related endpoints (p = 0.037 and 0.018). Low to moderate signals of treatment effect heterogeneity were detected according to individualized scores. A MS patient subgroup was identified for whom DMF was more effective than TERI (p = 0.013): older (45 versus 38 years), longer MS duration (110 versus 50 months), not newly diagnosed (74% versus 40%), and no prior glatiramer acetate usage (35% versus 5%).Conclusion: The implemented approach can disentangle prognostic differences from treatment effect heterogeneity and provide unbiased patient-specific profiling of comparative effectiveness based on real-world data.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231194353"},"PeriodicalIF":2.8,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9d/96/10.1177_20552173231194353.PMC10460475.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10307642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model. 利用治疗序列模型估算抗 CD20 治疗复发性多发性硬化症的健康经济效益。

IF 2.5

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2023-07-24 eCollection Date: 2023-07-01 DOI: 10.1177/20552173231189398

Ide Smets, Matthijs Versteegh, Simone Huygens, Cato Corsten, Beatrijs Wokke, Joost Smolders

{"title":"Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model.","authors":"Ide Smets, Matthijs Versteegh, Simone Huygens, Cato Corsten, Beatrijs Wokke, Joost Smolders","doi":"10.1177/20552173231189398","DOIUrl":"10.1177/20552173231189398","url":null,"abstract":"Background: In high-income countries, four anti-CD20 monoclonal antibodies (mAbs) are used or in the pipeline for relapsing MS: ocrelizumab, ofatumumab (both registered), ublituximab (awaiting registration) and rituximab (off-label). List prices differ significantly between registered and off-label drugs.Objective: Comparing differences in benefits between anti-CD20 mAbs from a health-economic and societal perspective.Methods: To reflect lifetime use of DMTs, we used a treatment-sequence model to compare ocrelizumab/ofatumumab and eight other drug classes in terms of health (lifetime relapses, time to Expanded Disability Status Scale [EDSS] 6, lifetime quality-adjusted life years) and cost-effectiveness (net health benefit). To become cost-effective compared to ocrelizumab, we modelled the list price of ublituximab and desired effect on EDSS progression of rituximab.Results: Although drug sequences with ocrelizumab in first- and second-line were more cost-effective than ofatumumab, our probabilistic analysis suggests this outcome was very uncertain. To be more cost-effective than ocrelizumab, ublituximab needs to be about 25% cheaper whilst rituximab needs to equal the effect on disability progression seen with first-line treatments.Conclusions: Our model showed no clear difference in cost-effectiveness between ocrelizumab and ofatumumab. Hence, prescribing the least costly anti-CD20 mAb can democratise MS care without a loss in health benefits.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231189398"},"PeriodicalIF":2.5,"publicationDate":"2023-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10301066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pre-training working memory/information processing capabilities and brain atrophy limit the improving effects of cognitive training. 训练前的工作记忆/信息处理能力和脑萎缩限制了认知训练的改善效果。

IF 2.8

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2023-07-01 DOI: 10.1177/20552173231196990

Sónia Félix Esbrí, Alba Sebastián Tirado, Maria Zaragoza Mezquita, Carla Sanchis Segura, Cristina Forn

{"title":"Pre-training working memory/information processing capabilities and brain atrophy limit the improving effects of cognitive training.","authors":"Sónia Félix Esbrí, Alba Sebastián Tirado, Maria Zaragoza Mezquita, Carla Sanchis Segura, Cristina Forn","doi":"10.1177/20552173231196990","DOIUrl":"https://doi.org/10.1177/20552173231196990","url":null,"abstract":"Background: Computerized training in persons with multiple sclerosis (PwMS) seems to enhance working memory (WM)/information processing (IP), but factors associated with the efficacy of the treatment have not been sufficiently explored. Objective: To identify clinical and radiological characteristics associated with positive WM/IP training responses.Methods: Radiological and neuropsychological assessments were carried out on a sample of 35 PwMs who were divided into \"WM/IP-impaired\" and \"WM/IP-preserved.\" All participants underwent adaptive n-back training for 10 days and were assessed post-training. Between-group differences (\"WM/IP-impaired\" vs. \"WM/IP-preserved\") in training-induced cognitive improvement were assessed and exploratory correlational/ regression-based methods were employed to assess the relationship between cognitive improvement and clinical and radiological variables.Results: All PwMS exhibited WM/IP benefits after training, but those with preserved WM/IP functions showed greater positive effects as well as transfer effects to other WM/IP tests when compared to the impaired group. Additional analyses revealed that positive response to treatment was associated with WM/IP baseline capabilities and greater gray matter volume (GMVOL) in relevant areas such as the thalamus.Conclusions: Restorative cognitive training is suitable to improve cognition in PwMS but its effective outcome differs depending on the baseline WM/IP capabilities and GMVOL.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231196990"},"PeriodicalIF":2.8,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/30/66/10.1177_20552173231196990.PMC10483983.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10275569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sleep disturbance and fatigue in multiple sclerosis: A systematic review and meta-analysis. 多发性硬化症的睡眠障碍和疲劳:一项系统回顾和荟萃分析。

IF 2.8

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2023-07-01 DOI: 10.1177/20552173231194352

Jagriti Jackie Bhattarai, Krina S Patel, Katherine M Dunn, Aeysha Brown, Brett Opelt, Abbey J Hughes

{"title":"Sleep disturbance and fatigue in multiple sclerosis: A systematic review and meta-analysis.","authors":"Jagriti Jackie Bhattarai, Krina S Patel, Katherine M Dunn, Aeysha Brown, Brett Opelt, Abbey J Hughes","doi":"10.1177/20552173231194352","DOIUrl":"https://doi.org/10.1177/20552173231194352","url":null,"abstract":"Sleep disturbance is common in people with multiple sclerosis and may worsen fatigue; however, the assessment of sleep-fatigue relationships varies across studies. To better understand sleep-fatigue relationships in this population, we conducted a systematic review and random effects meta-analyses for the associations between fatigue and 10 sleep variables: Sleep-disordered breathing, daytime sleepiness, sleep quality, insomnia, restless legs, number of awakenings, sleep efficiency, sleep latency, sleep duration, and wake after sleep onset. Of the 1062 studies screened, 46 met inclusion criteria and provided sufficient data for calculating Hedges' g. Study quality was assessed using the Newcastle-Ottawa Scale. Sample characteristics did not differ between the 10 analyses. Results indicated that sleep quality and insomnia (assessed via self-report or diagnostic criteria) were strongly associated with fatigue (all gs ≥ 0.80 and all ps < .001). In contrast, the number of awakenings and sleep duration (assessed objectively) were not significantly associated with fatigue. Remaining sleep variables yielded moderate, significant effects. Most effects did not vary based on study quality or sample demographics. Results highlight that insomnia and perceptions of poor sleep have a stronger link than objective sleep duration to fatigue in multiple sclerosis and may represent a more effective target for intervention.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231194352"},"PeriodicalIF":2.8,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a5/bd/10.1177_20552173231194352.PMC10460472.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10307640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Letter to the editor on "new algorithmic approach for easier and faster extended disability status scale calculation". 致编辑的信“新的算法方法更容易和更快地延长残疾状态量表的计算”。

IF 2.8

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2023-07-01 DOI: 10.1177/20552173231198378

Amr M Fouad

引用次数: 0